Alerts will be sent to your verified email
Verify EmailJUBLPHARMA
Jubilant Pharmova
|
Pfizer
|
Strides Pharma Scien
|
|
---|---|---|---|
Operational Metrics
|
|||
API Sector
|
|||
Australia DMF fillings
|
14.0 . | n/a | n/a |
US DMF Filings
|
98.0 . | n/a | n/a |
Canada DMF fillings
|
40.0 . | n/a | n/a |
Japan DMF Filings
|
15.0 . | n/a | n/a |
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
100.0 . | n/a | 260.0 . |
Number of ANDA's Approved By USFDA
|
62.0 . | n/a | 235.0 . |
Number of ANDA's Filed in Europe
|
38.0 | n/a | n/a |
Number of ANDA's Approved in Europe
|
37.0 | n/a | n/a |
Number of ANDA's Filed in Canada
|
24.0 | n/a | n/a |
Number of ANDA's Approved by Canada
|
24.0 | n/a | n/a |
R&D as a % of Total Sales
|
0.61 % | n/a | 2.24 % |
Financials
|
|||
5 yr Average ROE
|
10.45 % | 18.17 % | -1.06 % |
5yr average Equity Multiplier
|
2.05 | 1.31 | 2.7 |
5yr Average Asset Turnover Ratio
|
0.64 | 0.6 | 0.45 |
5yr Avg Net Profit Margin
|
8.17 % | 23.14 % | 0.77 % |
Price to Book
|
1.98 | 5.95 | 4.01 |
P/E
|
283.16 | 38.75 | 0.0 |
5yr Avg Cash Conversion Cycle
|
-3.54 Days | -26.61 Days | -89.35 Days |
Inventory Days
|
78.49 Days | 48.38 Days | 71.49 Days |
Days Receivable
|
54.89 Days | 20.98 Days | 73.25 Days |
Days Payable
|
167.25 Days | 83.8 Days | 261.28 Days |
5yr Average Interest Coverage Ratio
|
4.68 | 173.5 | 0.64 |
5yr Avg ROCE
|
10.85 % | 23.74 % | 6.23 % |
5yr Avg Operating Profit Margin
|
20.24 % | 35.56 % | 14.43 % |
5 yr average Debt to Equity
|
0.71 | 0.0 | 1.04 |
5yr CAGR Net Profit
|
n/a | 69.5 % | n/a |
5yr Average Return on Assets
|
5.11 % | 13.93 % | -0.26 % |
Shareholdings
|
|||
Promoter Holding
|
50.68 % | 63.92 % | 25.88 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 72.7 % |
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.0 | -3.79 % |
Change in Mutual Fund Holding (3 Yrs)
|
1.49 % | -0.7 % | -4.24 % |
Jubilant Pharmova
|
Pfizer
|
Strides Pharma Scien
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Segment Break-Up
|
Segment Break-Up
|
-
|
-
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
Operating Profit Break-Up
|
Capex
|
Capex
|
-
|
-
|
Asset Break-Up
|
Asset Break-Up
|
-
|
Asset Break-Up
|